Navigation Links
IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
Date:4/4/2008

IRVINE, Calif., April 4, 2008 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) announced today the appointment of Gregory J. Tibbitts to its board of directors, effective April 3, 2008. Mr. Tibbitts is currently the chief financial officer for CryoCor, Inc. (Nasdaq: CRYO), a San Diego-based medical device company and in this role has overseen the transition from a private to public company, as well as from a clinical stage company to the current commercial operation.

"Greg's extensive financial experience will be an asset to IDM Pharma's board of directors," said Timothy P. Walbert, president and chief executive officer of IDM Pharma. "In senior positions at both privately-held and publicly-traded companies, Greg has proven himself to be an executive with strong integrity and outstanding leadership abilities."

During his more than 19 years in the financial and pharmaceutical industries, Mr.Tibbitts has held senior positions in a number of other companies including chief financial officer at Elitra Pharmaceuticals, a privately held drug discovery company. In addition, Mr. Tibbitts served as senior manager at Ernst & Young LLP and division controller at ITT Residential Capital.

Mr. Tibbitts received a bachelor's degree from the University of San Diego and a master's degree from San Diego State University, and is a Certified Public Accountant.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's business activities and Mr. Tibbitts' participation on the Company's Board of Directors. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to provide assurance regarding the quality of the existing L-MTP-PE data and to respond to the remaining issues with regard to the MAA, including verification of data quality and CMC items, to the satisfaction of the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
3. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
4. Excipients Help Pharma Extend Product Life, Profits
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
7. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
8. Laureate Pharma Reports Record Growth for 2007
9. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. Dragon Pharma announces 2007 full year financial results
11. Transgenomic Opens Pharmacogenomics Laboratory in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the "Implantable Biomaterials ... report to their offering. Report Highlights: ... detailed analysis on current and future market trends to identify the investment ... as the base numbers Key market trends across the ...
Breaking Biology Technology:
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):